MIRA INFORM REPORT

 

 

Report Date :

03.06.2008

 

 

IDENTIFICATION DETAILS

 

Name :

KYORITSU SEIYAKU CORPORATION

 

 

Registered Office :

1-5-10 Kudanminami Chiyodaku Tokyo 102-0074

 

 

Country :

Japan

 

 

Financials (as on) :

31.05.2007

 

 

Date of Incorporation :

May 1955

 

 

Legal Form :

Limited Company (Kabushiki Kaisha)

 

 

Line of Business :

Import, Export, Wholesale of Veterinary Medicines

 

 

RATING & COMMENTS

 

MIRA’s Rating :

Ba

 

RATING

STATUS

PROPOSED CREDIT LINE

41-55

Ba

Overall operation is considered normal. Capable to meet normal commitments.

Satisfactory

 

Maximum Credit Limit :

YEN 797.9 Million

 

 

Status :

Satisfactory

 

 

Payment Behaviour :

Regular

 

 

name & address

 

KYORITSU SEIYAKU CORPORATION

REGD NAME:   Kyoritsu Seiyaku KK (Seiyaku means Pharmaceuticals)

MAIN OFFICE:  1-5-10 Kudanminami Chiyodaku Tokyo 102-0074 JAPAN

                        Tel: 03-3263-2931    

 

URL:                 http://www.kyoritsuseiyaku.co.jp/

E-Mail address:kyoritsu@kyoritsuseiyaku.co.jp

 

 

ACTIVITIES  

 

Import, export, wholesale of veterinary medicines

 

 

BRANCHES

 

Sapporo, Sendai, Saitama, Osaka, Nagoya, Okayama, Fukuoka, Kagoshima

 

 

FACTORY(IES)   

 

Daiba (Tokyo), Samukawa (--warehousing)

 

 

OFFICER(S)

 

Yuriko Takai, ch                                    

YUHEI OKAMOTO, PRES

Takaaki Takai, v pres                             

Seiichi Hirano, mgn dir

Kazuhiro Fujita, dir                                

Masataka Terakado, dir

 

 

Yen Amount

 

In million Yen, unless otherwise stated

 

 

SUMMARY

 

FINANCES        FAIR                             A/SALES          Yen 16,296 M

PAYMENTS      REGULAR                     CAPITAL           Yen 55 M

TREND             STEADY                       WORTH            Yen 11,328 M

STARTED         1955                             EMPLOYES      252

 

 

 

COMMENT

 

TRADING HOUSE SPECIALIZING IN VETERINARY MEDICINES. 

FINANCIAL SITUATION CONSIDERED FAIR TO GOOD AND RESPONSIBLE FOR ORDINARY BUSINESS ENGAGEMENTS.

 

 

MAX CREDIT LIMIT

 

YEN 797.9 MILLION, 30 DAYS NORMAL TERMS.

 

 

HIGHLIGHTS

 

The subject company is a leading trading house specializing in animal medicines, established by Yuriko Takei’s husband.  Specializes in import and wholesale of veterinary drugs, all for prescription by veterinary surgeons, such as vaccine, vitamins, etc.  Also handles pulicide, antibacterial agents, anthelmintic agents, pet foods, supplement foods, all for animals.  Animal feeds are also handled.  Nation’s top-ranked wholesaler of animal drugs.  Have wide business tie-ups with overseas mfrs, such as Fort Dodge Animal Health, Master Foods, Inter-bet International, Abbot Laboratories, Animal Health Options, Addison Biological Laboratory, other.  Domestic clients include pharmaceuticals mfrs, wholesalers, other. 

           

 

 

FINANCIAL INFORMATION

 

The sales volume for May/2007 fiscal term amounted to Yen 16,296 million, a 9% up from Yen 14,929 million in the previous term.  Demand for animal drugs grew rapidly amid pet booms nationwide, particularly by retired elderly population.  The recurring profit was posted at Yen 2,056 million and the net profit at Yen 11,218 million, respectively, compared with Yen 2,002 million recurring profit and Yen 1,100 million net profit, respectively, a year ago.

 

For the term just ended May 2008 the recurring profit was projected at Yen 2,400 million and the net profit at Yen 1,400 million, respectively, on a 13% rise in turnover, to Yen 18,400 million.  Business continues on the upswing.

 

The financial situation is considered FAIR to GOOD and responsible for ORDINARY business engagements.  Max credit limit is estimated at Yen 797.9 million, on 30 days normal terms.

 

 

REGISTRATION

 

Date Registered:            May 1955

Legal Status:                 Limited Company (Kabushiki Kaisha)

Authorized:                    280,000 shares

Issued:                          110,000 shares

Sum:                            Yen 55 million

 

 

 

 

 

Major shareholders (%)

 

Yuriko Takai (54), Takaaki Takai (25), Yuhei Okamoto (10)

No. of shareholders: 10

           

Nothing detrimental is known as to the commercial morality of executives.

 

 

OPERATION

 

Activities: Imports and wholesales veterinary prescription animal drugs: vaccine, vitamin,     antibacterial agents, anthelmintic agents, animal feeds, pet foods, supplement, other           (--100%).

 

 

Clients: [Pharmaceutical firms, traders] Aesop Yakuhin, Morikubo Yakuhin, Asuko, Atol Co, Sun Daiko, Maruzen Yakuhin, other.

 

 

No. of accounts

 

1,000

 

 

Domestic areas of activities

 

Nationwide

 

 

Suppliers

 

[Mfrs, wholesalers] Master Foods, Toray Ind, Kyowa Hakko Kogyo, Idemitsu          Kosan Co, Suntory Ltd, other.    

Goods are also imported.

 

 

Payment record

 

Regular

 

 

Location

 

Business area in Tokyo.  Office premises at the caption address are owned and maintained satisfactorily.

 

 

Bank References

 

Mizuho Bank (Kudan)

MUFG (Shin-Marunouchi)

Relations: Satisfactory

 

 

FINANCES: (In Million Yen)

 

       Terms Ending:

31/05/2008

31/05/2007

31/05/2006

31/05/2005

Annual Sales

 

18,400

16,296

14,929

13,505

Recur. Profit

 

2,400

2,056

2,002

1,451

Net Profit

 

1,400

1,238

1,100

964

Total Assets

 

 

15,239

15,031

14,861

Current Assets

 

 

9,641

9,518

9,107

Current Liabs

 

 

1,684

2,220

2,508

Net Worth

 

 

11,328

10,199

9,253

Capital, Paid-Up

 

 

55

55

55

Div.P.Share(¥)

 

 

1000.00

1000.00

500.00

<Analytical Data>

(%)

(%)

(%)

(%)

       S.Growth Rate

12.91

9.16

10.54

3.48

       Current Ratio

 

..

572.51

428.74

363.12

       N.Worth Ratio

..

74.34

67.85

62.26

       R.Profit/Sales

 

13.04

12.62

13.41

10.74

       N.Profit/Sales

7.61

7.60

7.37

7.14

      Return On Equity

..

10.93

10.79

10.42

 

Notes: Forecast (or estimated) figures for the 31/05/2008 fiscal term.

 

           

 

 


 

RATING EXPLANATIONS

 

RATING

STATUS

 

 

PROPOSED CREDIT LINE

>86

Aaa

Possesses an extremely sound financial base with the strongest capability for timely payment of interest and principal sums

 

Unlimited

71-85

Aa

Possesses adequate working capital. No caution needed for credit transaction. It has above average (strong) capability for payment of interest and principal sums

 

Large

56-70

A

Financial & operational base are regarded healthy. General unfavourable factors will not cause fatal effect. Satisfactory capability for payment of interest and principal sums

 

Fairly Large

41-55

Ba

Overall operation is considered normal. Capable to meet normal commitments.

 

Satisfactory

26-40

B

Unfavourable & favourable factors carry similar weight in credit consideration. Capability to overcome financial difficulties seems comparatively below average.

 

Small

11-25

Ca

Adverse factors are apparent. Repayment of interest and principal sums in default or expected to be in default upon maturity

 

Limited with full security

<10

C

Absolute credit risk exists. Caution needed to be exercised

 

 

Credit not recommended

NR

In view of the lack of information, we have no basis upon which to recommend credit dealings

No Rating

 

 

This score serves as a reference to assess SC’s credit risk and to set the amount of credit to be extended. It is calculated from a composite of weighted scores obtained from each of the major sections of this report. The assessed factors and their relative weights (as indicated through %) are as follows:

 

Financial condition (40%)            Ownership background (20%)                 Payment record (10%)

Credit history (10%)                    Market trend (10%)                                Operational size (10%)

 

 

 

 

PRIVATE & CONFIDENTIAL : This information is provided to you at your request, you having employed MIPL for such purpose. You will use the information as aid only in determining the propriety of giving credit and generally as an aid to your business and for no other purpose. You will hold the information in strict confidence, and shall not reveal it or make it known to the subject persons, firms or corporations or to any other. MIPL does not warrant the correctness of the information as you hold it free of any liability whatsoever. You will be liable to and indemnify MIPL for any loss, damage or expense, occasioned by your breach or non observance of any one, or more of these conditions